Welcome to Crene Biotechnology!


Product :

Eravacycline(TP-434) dihydrochloride

Eravacycline(TP-434) dihydrochloride 1334714-66-7
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:Eravacycline(TP-434) dihydrochloride Purity:98% min
CAS NO:1334714-66-7 Solubility:Soluble in DMSO
Molecular Formula:C27H33Cl2FN4O8 Package:Packaging according to customer requirements
Molecular Weight:631.48 Storage:Store at -20℃
Quality control
Eravacycline dihydrochloride (TP-434 dihydrochloride) is a potent and broad-spectrum antibacterial agent.Eravacycline is potent antibiotic against A. baumannii, including isolates that are resistant to sulbactam, imipenem/meropenem, levofloxacin, and amikacin/tobramycin. Eravacycline shows greater activity than the comparators of the tetracycline class, levofloxacin, amikacin, tobramycin, and colistin. The eravacycline MIC50/90 values are 0.5/1 mg/L[1]. Eravacycline shows inhibitory effects on six E. coli with MICs ranging from 0.125 to 0.25 mg/L[2]. Eravacycline dihydrochloride is a synthetic antibiotic, with inhibits bacterial protein synthesis through binding to the 30S ribosomal subunit. Eravacycline displays broad spectrum activity against gram-negative bacteria in the panel except P. aeruginosa, as well as excellent activity against major gram-positive pathogens, including methicillin-resistant S. aureus. Eravacycline also displays potent ribosomal inhibition[3]. Eravacycline shows potent broad-spectrum activity against 90% of the isolates (MIC90) in each panel at concentrations ranging from ≤0.008 to 2 μg/mL for all species panels except those of Pseudomonas aeruginosa and Burkholderia cenocepacia ((MIC90) values of 32 μg/mL for both organisms). Eravacycline is active against multidrug-resistant bacteria, including those expressing extended-spectrum β-lactamases and mechanisms conferring resistance to other classes of antibiotics, including carbapenem resistance[4].Mice are treated with two-fold increasing doses (range 3.125 to 50 mg/kg) of eravacycline every 12 hours. The mean fAUC/MIC magnitude associated with net stasis and 1-log kill endpoint are 27.97 ± 8.29 and 32.60 ± 10.85, respectively[2]. Eravacycline is active in multiple murine models of infection against clinically important Gram-positive and Gram-negative pathogens. Eravacycline is efficacious in mouse septicemia models, demonstrating 50% protective dose values of ≤1 mg/kg of body weight once a day (q.d.) against Staphylococcus aureus, including tetracycline-resistant isolates of methicillin-resistant S. aureus (MRSA), and Streptococcus pyogenes. The PD50 values against Escherichia coli isolates are 1.2 to 4.4 mg/kg q.d[5].
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China